POS0714 TREAT-TO-TARGET RECOMMENDATIONS IN GIANT CELL ARTERITIS AND POLYMYALGIA RHEUMATICA
Authors: C. Dejaco, A. Kerschbaumer, D. Aletaha, M. Bond, E. Hysa, D. Camellino, L. Ehlers, A. Abril, S. Appenzeller, M. C. Cid, B. Dasgupta, C. Duftner, P. Grayson, B. Hellmich, A. Hocevar, T. Kermani, E. Matteson, S. Mollan, L. Neill, C. Ponte, C. Salvarani, S. E. Sattui, W. A. Schmidt, P. Seo, J. Smolen, J. Thiel, C. Toro Gutiérrez, M. Whitlock, F. Buttgereit
Journal: Annals of the Rheumatic Diseases (2023)

<h3>Background</h3> The treat-to-target (T2T) concept is not yet a recognized treatment approach in giant cell arteritis (GCA) and polymyalgia rheumatica (PMR). Developing such recommendations is an unmet medical need. <h3>Objectives</h3> To determine therapeutic targets and develop treat-to-target (T2T) recommendations in GCA and PMR. <h3>Methods</h3> We conducted a systematic literature review to retrieve data on treatment targets and outcomes in GCA/PMR as well as to identify the evidence for the effectiveness of T2T-based management approaches in these diseases. Based on evidence and expert opinion, the task force [29 participants from 10 countries (physicians, healthcare professional and patient)] developed recommendations, with consensus obtained through voting. The final level of agreement was provided anonymously. <h3>Results</h3> Five overarching principles and six specific recommendations were formulated (Table 1). Key messages are that the management of GCA and PMR should be based on shared decisions between patient and physician, underpinning the need for urgent treatment of GCA to avoid ischemic complications, and that it should aim at maximizing health-related quality of life in both diseases. The treatment targets are the achievement and maintenance of remission (still in need of ultimate validation), as well as prevention of tissue ischemia and vascular damage. Comorbidities should be considered when assessing disease activity and selecting treatment. <h3>Conclusion</h3> These are the first T2T recommendations for GCA and PMR. Treatment targets and strategies to assess, achieve and maintain these targets have been defined. The research agenda highlights the evidence-gaps and needs for future research. <h3>Acknowledgements</h3> Funding to conduct this project has been provided by AbbVie. The authors would like to thank Louise Falzon for her work in the development of the literature search strategy. <h3>Disclosure of Interests</h3> Christian Dejaco Speakers bureau: Abbvie, Eli Lilly, Janssen, Novartis, Pfizer, Roche, Galapagos and Sanofi, Consultant of: Abbvie, Eli Lilly, Janssen, Novartis, Pfizer, Roche, Galapagos, Sparrow and Sanofi, Grant/research support from: AbbVie, Andreas Kerschbaumer Speakers bureau: AbbVie, Amgen, Bristol-Myers Squibb, Eli Lilly, Gilead, Janssen, Merck Sharp and Dohme, Novartis, UCB and Pfizer, Consultant of: AbbVie, Amgen, Bristol-Myers Squibb, Eli Lilly, Gilead, Janssen, Merck Sharp and Dohme, Novartis, UCB and Pfizer, Daniel Aletaha Speakers bureau: Abbvie, Amgen, Galapagos, Lilly, Janssen, Merck, Novartis, Pfizer, Sandoz, and Sanofi, Consultant of: Abbvie, Amgen, Galapagos, Lilly, Janssen, Merck, Novartis, Pfizer, Sandoz, and Sanofi, Grant/research support from: Abbvie, Amgen, Galapagos, Lilly, Janssen, Merck, Novartis, Pfizer, Sandoz, and Sanofi, Milena Bond: None declared, Elvis Hysa: None declared, Dario Camellino Speakers bureau: Abiogen, BMS and GSK, Lisa Ehlers: None declared, Andy Abril: None declared, Simone Appenzeller: None declared, Maria C. Cid Speakers bureau: GSK and SCL-Vifor, Consultant of: GSK, Vifor, Abbvie, and Janssen, Grant/research support from: Kiniksa Pharmaceuticals, Bhaskar Dasgupta Speakers bureau: Chugai, Consultant of: Novartis, Abbvie, Roche, Christina Duftner Speakers bureau: Abbvie, AOP Orphan, Astra-Zeneca, Bristol-Myers-Squibb, Eli-Lilly, Janssen, Galapagos, Merck-Sharp-Dohme, Novartis, Pfizer, Roche, Sandoz, UCB, Vifor, Consultant of: Abbvie, AOP Orphan, Astra-Zeneca, Bristol-Myers-Squibb, Eli-Lilly, Janssen, Galapagos, Merck-Sharp-Dohme, Novartis, Pfizer, Roche, Sandoz, UCB, Vifor, Grant/research support from: Eli-Lilly, Pfizer, UCB, Peter Grayson: None declared, Bernhard Hellmich Speakers bureau: Abbvie, Amgen, Astra-Zeneca, BMS, Boehringer, Chugai, GSK, InflaRx, Janssen, MSD, Pfizer, Novartis, Phadia, Roche and Vifor, Consultant of: Abbvie, Amgen, Astra-Zeneca, BMS, Boehringer, Chugai, GSK, InflaRx, Janssen, MSD, Pfizer, Novartis, Phadia, Roche and Vifor, ALOJZIJA HOCEVAR: None declared, Tanaz Kermani: None declared, Eric Matteson Speakers bureau: Boehringer-Ingelheim, Consultant of: Boehringer-Ingelheim, Horizon Therapeutics, Alvotech Inc, Susan Mollan Speakers bureau: Heidelberg engineering; Chugai-Roche Ltd; Allergan; Santen; Teva UK; Chiesi; and Santhera, Consultant of: Invex Therapeutics, Gensight, Lorna Neill: None declared, Cristina Ponte Speakers bureau: Vifor, AstraZeneca, GlaxoSmithKline, and Roche, Consultant of: Vifor, AstraZeneca, GlaxoSmithKline, and Roche, Grant/research support from: AbbVie, Sanofi and Novartis, Carlo Salvarani Speakers bureau: Abbvie, Boehringer-Ingelheim, Eli Lilly, Galapagos, Novartis, Pfizer and Roche, Consultant of: Abbvie, Boehringer-Ingelheim, Eli Lilly, Galapagos, Novartis, Pfizer and Roche, Sebastian E. Sattui Grant/research support from: Astra-Zeneca, Rheumatology Research Foundation RISE pilot award and Bristol Myers Squibb Foundation Robert A. Winn Diversity in Clinical Trials Career Development Award, Wolfgang A. Schmidt Speakers bureau: Abbvie, Amgen, Bristol-Myers Squibb, Chugai, GlaxoSmithKline, Johnson &amp; Johnson, Medac, Novartis, Roche, and Sanofi, Consultant of: Abbvie, Amgen, Bristol-Myers Squibb, Chugai, GlaxoSmithKline, Johnson &amp; Johnson, Medac, Novartis, Roche, and Sanofi, Grant/research support from: Abbvie, Amgen, GlaxoSmithKline, Novartis, Roche and Sanofi, Philip Seo Consultant of: Amgen and Janssen, Josef Smolen Speakers bureau: AbbVie, Amgen, AstraZeneca, Astro, Bristol-Myers Squibb, Celltrion, Chugai, Gilead, Janssen, Lilly, Merck Sharp &amp; Dohme, Novartis-Sandoz, Pfizer, R-Pharm, Roche, Samsung, Sanofi, and UCB, Consultant of: AbbVie, Amgen, AstraZeneca, Astro, Bristol-Myers Squibb, Celltrion, Chugai, Gilead, Janssen, Lilly, Merck Sharp &amp; Dohme, Novartis-Sandoz, Pfizer, R-Pharm, Roche, Samsung, Sanofi, and UCB, Grant/research support from: Abbvie, AstraZeneca, Lilly, Novartis and Roche, Jens Thiel Speakers bureau: Bristol-Myers-Squibb, Novartis, Glaxo-Smith-Kline, Astra-Zeneca, Janssen, Abbvie, Eli-Lilly, Consultant of: Bristol-Myers-Squibb, Novartis, Glaxo-Smith-Kline, Astra-Zeneca, Janssen, Abbvie, Eli-Lilly, CARLOS TORO GUTIÉRREZ Speakers bureau: Abbvie, BMS, Boehringer Ingelheim, Biopas, Janssen, Pfizer, Pharmalab, Roche, Consultant of: Abbvie, BMS, Boehringer Ingelheim, Biopas, Janssen, Pfizer, Pharmalab, Roche, Madeline Whitlock Speakers bureau: Roche, Frank Buttgereit Speakers bureau: Abbvie, Novartis, Pfizer, Roche, and Sanofi, Consultant of: Abbvie, Novartis, Pfizer, Roche, and Sanofi.